The last few months have marked a period of meaningful progress for our first affiliate company, @GRIN_tx, as we work to develop targeted treatments for individuals living with GRIN-NDD and other neurodevelopmental disorders. Learn more:

We stand alongside the @wfneurology to observe World Brain Day. Discover what today means for us and the patients we serve. Learn more about our mission to bring potential solutions to those in need:

In this @ClinicalLeader1 article, our CEO Bruce Leuchter, M.D., discusses how we are helping address the challenges of #neuroscience drug development through a novel private equity (PE)–based model. Read here:

See our press release:

We are excited to announce the appointment of Gail Farfel, PhD, to our board of directors. As a neuroscientist and life sciences executive, Dr. Farfel brings more than three decades of expertise in pharmaceutical development and regulatory strategy to Neurvati and @grin_tx.

At @SAPA_HQ’s 8th Annual Healthcare Investment Forum & Roadshow, our SVP, Corporate & Business Dev. Jay Lettiere will participate in a panel discussion on how strategic collaborations are essential to advancing the missions of both Neurvati & @GRIN_tx:

We’re excited to participate in #BIO2025! We look forward to engaging with like-minded leaders to explore how we can collaborate and advance new treatments for patients impacted by neurological and psychiatric disorders. Schedule a meeting with us:

Last week, we joined industry leaders at the 18th Conference on Epilepsy Therapies & Diagnostic Development. We left with a deeper understanding of where the field is headed, and a renewed commitment to translating these insights into meaningful progress for patients & families.

We look forward to joining leaders from academia and industry at the 18th Conference on Epilepsy Therapies & Diagnostic Development, hosted by the Epilepsy Study Consortium in collaboration with @Penn and the @EpilepsyFdn.

Our partnership with @AngeliniPharma further validates the strength of our business strategy to unlock the potential of promising #neuroscience assets through focused, mid-to-late-stage development. We’re excited about the progress we’re making and the future ahead!.

We’re excited to welcome Michael Lieberman as Senior Director of Medical Communications at Neurvati and @GRIN_tx. With over 20 years of experience, he will lead the development & execution of our medical communications strategy.

This week, our CEO Bruce Leuchter, M.D., will be attending the PJT Partners Biopharma Innovators Summit, where leaders in the #biopharma industry will gather to discuss groundbreaking innovations and strategies shaping the future of healthcare.

We are pleased to welcome Marjory Levey as Executive Director of Medical Affairs. With over 20 years of experience in #CNS disorders, Marjory brings a wealth of expertise in developing and executing medical strategies.

This positive opinion for investigational radiprodil underscores our commitment to advancing this important research and helps bring us one step closer to addressing the urgent needs of patients and families affected by GRIN-NDD.

What an incredible experience at the #WorldOrphanDrugCongress! The event underscored the urgent need for more effective treatments for rare diseases and highlighted the critical importance of accelerating drug discovery to tackle these challenges. #WODC.

Happy #AdministrativeProfessionalsDay! Today, we honor our incredible administrative professionals and the vital role they play in supporting our team, as well as the patients and families we serve.

During the #WorldOrphanDrugCongress, Jason Lettiere, will join industry leaders for a panel discussion on “Unveiling Promising Strategies: Drug Discovery for Rare Disease Treatments.” See the agenda: #WODC

Recent advances in treating developmental and epileptic encephalopathies and pediatric epilepsies have been driven by whole exome sequencing, allowing development of targeted therapies & more individualized treatments. Learn more from @AmerAcadPeds:

Our SVP of Corporate and Business Development, Jason Lettiere, discusses the pivotal role collaborations can play in accelerating the development of breakthrough treatments for neurological and neuropsychiatric disorders.

Excited for our CMO, Michael Panzara, to join the panel celebrating @NIH_NINDS' 75th Anniversary at the @AANMember Annual Meeting (Apr 5-9, San Diego)! Looking forward to insightful discussions on the latest in neurology. Learn more: #AANAM